Pharmaceuticals in Brazil M&A Movements Analysis¶
M&A Movements¶
Based on the available information for 2024 and early 2025, the most significant reported merger and acquisition (M&A) movement impacting the Brazilian pharmaceutical value chain is the proposed combination between two major national players: EMS and Hypera Pharma. In late 2024, privately owned EMS proposed a public tender offer to acquire a stake of up to 20% in Hypera Pharma, along with a stock swap, with the stated goal of creating the largest drug manufacturer in Brazil. The proposal was announced on October 21, 2024, with EMS offering R$30 per share, a premium over Hypera's stock price at the time. EMS indicated that the merger could potentially be finalized within 30 days and did not anticipate significant restrictions from Brazilian antitrust regulators.
Both EMS and Hypera Pharma leadership expressed agreement on the potential benefits of this industrial combination, highlighting its capacity to solidify their market-leading position and achieve a combined market share of 17% in segments such as prescription drugs, generics, and hospital treatments. This combined share would be more than double that of their next competitor, Eurofarma. The proposed merger aimed to leverage the strong brand portfolios of both companies, which include popular names like Buscopan, Benegrip, Neosaldina, and Engov.
Hypera Pharma confirmed receiving the acquisition proposal from EMS. However, Hypera initially rejected the merger proposal, citing a lack of alignment and seeking better terms for consideration. As of May 2025, the provided information does not confirm the finalization or current status of this proposed merger.
While the proposed EMS-Hypera merger stands out, the provided documents do not detail other major M&A movements specifically within the Brazilian pharmaceutical value chain during 2024 and 2025. Globally, the pharmaceutical M&A landscape in 2024 saw a trend towards smaller deals, although 2025 began with some larger transactions and a general expectation of increased dynamism in the market, driven by factors such as looming patent cliffs for major drugs and large pharmaceutical companies seeking to replenish their pipelines. Strategic acquisitions aimed at expanding the value chain and acquiring the latest technologies have been observed globally.
Table of the impact of these movements¶
The potential impact of the proposed EMS-Hypera merger on the Brazilian pharmaceutical value chain, based on the stated goals and general effects of M&A in the industry, can be summarized as follows:
| Value Chain Stage | Potential Impact of EMS-Hypera Merger | Notes |
|---|---|---|
| Input Production (Farmoquímica) | Limited direct impact on domestic API production given Brazil's high import dependence. Could potentially lead to consolidated purchasing power for imported APIs. | The core challenge of reliance on imported APIs (~90%) remains largely unaddressed by this merger focus. |
| Pharmaceutical Production | Significant increase in market concentration and leadership in generics, similars, prescription, and hospital segments. Potential for operational synergies, economies of scale, and optimized production processes. May lead to rationalization of product portfolios. | Creates the largest national manufacturer, intensifying competition for other players like Eurofarma. Potential for enhanced R&D capabilities through combined resources. |
| Distribution | Potentially streamlined distribution for the combined entity, leading to greater efficiency in reaching pharmacies and hospitals. Increased bargaining power over distributors for the merged company. | Could influence terms and relationships within the distribution network. |
| Retail & Commercialization | Increased presence and bargaining power in the retail segment due to combined product portfolio and market share in sales to pharmacies. May lead to intensified competition for other pharmacy chains. | Impacts relationships with large pharmacy chains and potentially influences product availability and promotional strategies at the retail level. |
| Overall Market Dynamics | Reduced competitive rivalry among the top national manufacturers. Potential for increased market power for the merged entity, potentially impacting pricing discussions (though still subject to CMED regulation). May stimulate further consolidation among other players. | Regulatory approval (CADE) would be a key factor in mitigating potential anti-competitive effects. |
Beyond the specific proposed merger, global M&A trends could also influence the Brazilian value chain. Acquisitions focused on expanding the value chain or acquiring new technologies, as seen internationally, could lead to foreign companies acquiring Brazilian assets or forming partnerships to enhance their presence or capabilities in the local market, particularly in areas like biotechnology or specialized manufacturing. Conversely, Brazilian companies might look for international acquisitions to gain access to new markets, technologies, or product pipelines.
The impact of M&A on supply chain vulnerabilities and potential drug shortages is a concern globally, and this could also be a consideration in the Brazilian context, particularly if mergers lead to product line reductions or manufacturing site consolidations.
References¶
Abradilan. Crescimento das grandes redes de farmácias. https://abradilan.com.br/crescimento-das-grandes-redes-de-farmacias/ Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor. https://abradilan.com.br/setor-farmaceutico-cresce-127-em-2024-mas-reajuste-autorizado-gera-duvidas-e-impacto-no-bolso-do-consumidor/ Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos. https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2024/nova-industria-brasil-contribuira-para-fortalecer-producao-de-medicamentos BNDES. Cadeia farmacêutica no Brasil: avaliação preliminar e perspectivas. https://www.bndes.gov.br/wps/portal/site/home/conhecimento/pesquisaetecnologia/estudossetoriais/cadeia-farmaceutica-brasil CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos. https://www.cnnbrasil.com.br/business/brasil-importa-90-da-materia-prima-para-a-producao-de-medicamentos/ Dr. Fisiologia. Indústria farmacêutica brasileira e suas tendências (2025). https://drfisiologia.com.br/industria-farmaceutica-brasileira-e-suas-tendencias-2025/ FIA. Indústria farmacêutica: características, setores e mercado de trabalho. https://fia.com.br/blog/industria-farmaceutica/ Global Legal Insights. Pricing & Reimbursement Laws and Regulations 2024 | Brazil. https://www.globallegalinsights.com/practice-areas/pricing-and-reimbursement-laws-and-regulations/brazil Global Regulatory Partners. OVERVIEW OF PRICING AND REIMBURSEMENT OF DRUGS REGISTRATION IN BRAZIL. https://www.globalregulatorypartners.com/overview-of-pricing-and-reimbursement-of-drugs-registration-in-brazil ICTQ. Os modelos de negócios farmacêuticos. https://ictq.com.br/varejo-farmaceutico/17472-os-modelos-de-negocios-farmaceuticos Ipea. Purchase of medicines by the Brazilian federal government. https://www.ipea.gov.br/portal/index.php?option=com_content&view=article&id=42562:compra-de-medicamentos-pelo-governo-federal-brasileiro&catid=11&lang=en&Itemid=10 Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://medicnasa.com.br/tres-grandes-grupos-de-redes-de-farmacias-concentram-40-do-mercado-no-brasil/ Medicina SA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bilhões em 2024. https://medicnasa.com.br/varejo-farmaceutico-cresce-11-e-movimenta-r-1584-bilhoes-em-2024/ NAVLIN DAILY. Brazil's CMED Sets New Maximum Price Adjustment Rates for Medicines in Pharmacies. https://navlin.com/news/brazils-cmed-sets-new-maximum-price-adjustment-rates-for-medicines-in-pharmacies Panorama Farmacêutico. Dez maiores laboratórios do Brasil têm 55% do mercado. https://panoramafarmaceutico.com.br/maiores-laboratorios-brasil/ Reuters. EMS proposes merger with Hypera to form Brazil's largest drugmaker. https://www.reuters.com/markets/deals/brazils-ems-proposes-merger-with-hypera-form-largest-drugmaker-2024-10-21/ Revista Espacios. Public Policies and Competitiveness in the Pharmaceutical Industry: The case of Brazil and India. https://www.revistaespacios.com/a18v39n39/18393905.html